The company's focus is on developing novel drugs that target a key enzymatic target in a lipid metabolism pathway, with initial emphasis on treating non-alcoholic steatohepatitis (NASH), a liver disease. Cincera's drugs have shown potent anti-inflammatory and anti-fibrotic properties and have potential applications in other disease areas including cancer. The company aims to have drug candidates ready for clinical trials by 2020/21 and is funded by the Medical Research Commercialisation Fund (MRCF) managed by Brandon Capital Partners (BCP).